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Background: Endometrial cancer is a common female malignancy. Patients with high-risk endometrial cancer have
relatively high incidence of metastasis and recurrence. Despite complete resection, patients with stage III or IV are at
high risk of local or distant recurrence. Systemic adjuvant treatment includes chemotherapy and radiotherapy. But the
optimal scheduling is not known. Recently proposed sequential chemo-radiotherapy as sandwich therapy for high risk
endometrial cancer have yielded encouraging results. This article is to review the adjuvant chemo-radiotherapy in the
“sandwich” method for high risk endometrial cancer to help clinicians identify the most effective adjuvant treatment
for patients with high risks of it.
Methods: We used MEDLINE, EMBASE, Cochrane Library and CBM databases to search the literature.
Results: A systematic review was made. And most data showed “sandwich” therapy is feasible, efficacious,
well-tolerated and resulted in excellent long-term progression free and overall survival in the setting of advanced
endometrial cancer.
Conclusion: Randomized trials are necessary to compare chemo-radio therapy given in the “sandwich” fashion
to other means of sequencing these treatment modalities. It is also necessary to define which population is best
suited for “sandwich” adjuvant therapy.
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Overall survival (OS)Background
Endometrial cancer is a common female malignancy. The in-
cidence varies because of different lifestyles and regions. In de-
veloped countries, the incidence rate is the highest among
female genital malignancies, and the age of patients become
younger. The prognosis is closely related to the disease stage.
If the diagnosis is during stage I, then the survival rate is about
90 %. But those with extra-uterine disease (stage III or IV)
have a significant risk of death despite current therapies, with
5- year survival rates ranging from 23 to 72% [1–4].
Despite complete resection, patients with stage III or IV
are at high risk of local or distant recurrence. Systemic ad-
juvant treatment includes chemotherapy and radiotherapy.* Correspondence: bjzhangzhy@sina.cn
1Department of Obstetrics and Gynecology, Beijng Chao-yang Hospital
affiliated to Capital Medical University, No. 8 Gongti South Road, Beijing
100020, P. R. China
Full list of author information is available at the end of the article
© 2015 Bie et al. This is an Open Access articl
(http://creativecommons.org/licenses/by/4.0),
provided the original work is properly credited
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posed sequential chemo-radiotherapy as sandwich therapy
for high risk endometrial cancer have yielded encouraging
results, while a single center experience shows that “sand-
wich chemo-radiotherapy” seems to be more toxic particu-
larly for patients who had pelvic and para- aortic
irradiation. Therefore, it might be more convenient to delay
radiotherapy after six cycles of chemotherapy for patients
with the indication of pelvic para-aortic radiotherapy [5].
The evaluation of high risks are according to patients’ age,
pathology grade, stage, histology type, lymphovascular space
invasion (LVSI), tumor size, myometrial invasion, parametrial
involvement, cervical stroma or vaginal disease and positive
pelvic or para-aortic nodes (Table 1). Patients with high-risk
endometrial cancer have relatively high incidence of metasta-
sis and recurrence. Therefore, adjuvant chemotherapy ande distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
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Tumor size ≥1/2 uterine cavity <1/2 uterine cavity
Myometrial invasion ≥1/2 <1/2







High-risk endometrial cancer criteria included, but were not limited to these
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relapse.
Adjuvant chemo-radiotherapy in the “sandwich” method
for high risk endometrial cancer has been described
consisting of initial chemotherapy of limited duration,
followed by radiotherapy, and then subsequent consoli-
dation chemotherapy again (CRC).
We made a systematic review about the adjuvant chemo-
radiotherapy in the “sandwich”method for high risk endomet-
rial cancer after surgery to help clinicians in identifying the
most effective adjuvant treatment for patients with high risks.
Methods
Search strategy and selection criteria
We systematically searched MEDLINE, EMBASE and
Cochrane Library databases (from their commencements
to February 2014), with no language restriction, for studies
in women of the association between endometrial cancerFig. 1 Selection process for articles included in the systematic reviewand adjuvant chemotherapy and radiotherapy in the
“sandwich” method. Index words included the medical
subject headings (MeSH) endometrial neoplasms and
uterine neoplasms, and the following text words: endo-
metrium, endometrial, uterus, uterine, cancer carcinoma,
chemotherapy, radiotherapy and adjuvant therapy. Trials
of adjuvant chemotherapy and radiotherapy only in “sand-
wich” method for EC were included. Search terms related
to study design and publication type included systematic
review, clinical trial, meta-analysis, controlled clinical tri-
als, and randomized controlled trials. Reference lists of
identified studies were scanned for additional citations
until no additional articles could be identified. Subjects
underwent surgical staging comprised of total hysterec-
tomy, bilateral salpingo-oophorectomy, bilateral pelvic
and para-aortic lymph node dissection and peritoneal cy-
tology. If a dataset had been published more than once,
we used the most recent publication (Fig. 1).
Results
There were 10 articles included in this review. Four of
them are prospective and five are retrospective studies
(Table 2). Another one is a review.
Prospective studies
Lupe et al. did a prospective cohort study to determine the
feasibility of adjuvant paclitaxel and carboplatin chemother-
apy with involved field radiotherapy for 43 patients with
stage III or IV uterine malignancies (40 carcinomas and 3
mixed Mullerian tumors, MMT’s). They concluded that
therapy in this way is associated with a low rate of local re-
currence and favorable survival for advanced endometrial
cancer. They previously reported the toxicity of this proto-
col. About 31 % of their patients experienced grade 3 or 4
toxicity with peripheral neuropathy and neutropenia [6].
Geller et al. did a phase II trial of carboplatin and do-
cetaxel followed by radiotherapy given in “Sandwich”
way for advanced and recurrent patients. They believed
Table 2 Summary of study details and patient characteristics from recent “sandwich” regimens
Study Design Drugs N Age (median and range) Stage Subtype (%)
EC SC CC Mixed
Lupe [6] P paclitaxel/carboplatin 43 IIIA-IVB 37 35 7 6
Geller [7] P docetaxel/carboplatin 41 59 IIIA-IVB 78 10 2
Einstein [8] P ifosfamide/cisplatin 27 I-IV uterine carcinosarcoma 100
Fields [9] P paclitaxel/platinum 30 69(45–82) I-IV uterine papillary serous
carcinoma (UPSC)
100
Secord [10] R paclitaxel/carboplatin 79 % 45 62(35–83 III-IV 48 17 5 28
Geller [11] R taxane/carboplatin 23 57(28–78) IIA-IVB(78 %III,13 %IV) 43 52 4
Abaid [12] R paclitaxel/carboplatin 32 67 IA-IVA 59 13 9 9
Lan [13] R docetaxel/carboplatin 35 53(23–69) IIIA-IVB 83
Dogan [5] R paclitaxel/carboplatin 11 63(36–83) IIIC 73 18 9
P Prospective Study, R Retrospective Study, N number, EC endometrioid adenocarcinoma, SS serous carcinoma, CC clear cell carcinoma
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icity. And patients had minimal delay between treatment
modalities [7].
The low rate of recurrence in the radiation field was
notable in both studies.
Another study did by Einstein et al. about phase II
trial of adjuvant pelvic radiation “sandwiched” between
ifosfamide or ifosfamide plus cisplatin in women with
uterine carcinosarcoma [8]. The 2 year DFS was similar
in both groups. The addition of cisplatin added toxicity
without improving efficacy. With ifosfamide alone, the
efficacy of the “sandwich” therapy comes with a moder-
ate but tolerable toxicity profile.
Fields et al. also had a prospective study on patients with
uterine papillary serous carcinoma (UPSC) to treat with
pelvic radiation “sandwiched” between six cycles of pacli-
taxel(T)/platinum(P) chemotherapy. They also showed the
radiation “sandwiched” between T/P chemotherapy is a
well-tolerated and efficacious regimen for patients with
completely resected UPSC [9].
Retrospective studies
There are also 5 retrospective studies to assess the sequen-
tial chemotherapy and radiotherapy as “sandwich” therapy
for the treatment of high risk endometrial cancer.
A multicenter retrospective analysis was done by
Secord. Similar to other studies, it showed that the most
common grades 3–4 chemotherapy toxicities were neu-
tropenia (33 %), anemia (19 %), and neurotoxicity (33 %)
in women treated in the “sandwich” manner. They
proved that sequential CRC (chemotherapy-radiotherapy-
chemotherapy) was associated with improved survival in
women with advanced stage disease compared to other
sequencing modalities with a similar adverse effect
profile [10].
Geller, et al. also conducted a retrospective analysis.
There were 23 patients of advanced stage of EC, themajorities were in stage III(78 %) and histological types
were serous (52 %), treated with comprehensive surgical
staging followed by adjuvant therapy in “sandwich”
method. It consisted of sequential chemotherapy and
pelvic radiation with or without para-aortic radiation. It
was feasible, well tolerated and resulted in excellent
long-term progression free and overall survival [11].
Abaid, et al. analyzed 32 endometrial cancer patients
who were treated with carboplatin and paclitaxel. 186 cy-
cles had been administered and 94 % of patients com-
pleted the planned. The incidence of grade 3
neutropenia is 3.1 % and no incidence of grade 4 neutro-
penia. Grade 3 anemia in 12.5 % of patients and grade 4
in 3.1 % of patients were observed. They proved the
hematologic toxicity was well tolerated and non-
hematologic toxicity was mild and easily managed. [12].
Lan, et al. retrospectively reviewed patients with
staged III - IV disease who received adjuvant chemother-
apy (docetaxel plus carboplatin) administered alone or
interposed with radiotherapy. In all 35 patients, 25 pa-
tients with stage IIIC - IVB disease and 1 patient with
stage IIIA disease received radiotherapy sandwiched be-
tween chemotherapy cycles (total, three to six cycles).
They showed the sandwich therapy is efficacious and
well tolerated for stage IIIC - IVB endometrial cancer.
And they also showed adjuvant chemotherapy alone
with docetaxel and carboplatin might be sufficient for
stage IIIA disease [13].
Most data supports that sandwich therapy is feasible,
efficacious, well tolerated and resulted in excellent long-
term progression free and overall survival in the setting
of advanced endometrial cancer.
While Dagon, et al. got an opposite conclusion. They
compared “sandwich therapy” with six cycles of chemo-
therapy followed by adjuvant radiotherapy with respect
to tolerability and acute toxicity. 25 patients with stage
IIIC endometrial cancer were treated with either three





Lupe [6] 43 45Gy 4CT+RT+2CT 6CT
Geller [7] 41 45Gy 3CT+RT+3CT 6CT
Einstein [8] 27 45Gy 3CT+RT+3CT 6CT
Fields [9] 30 45Gy 3CT+RT+3CT 6CT
Secord [10] 45 3CT+RT+CT 6 ~ 9CT
Geller [11] 23 45Gy 2/3/4CT+RT+CT 2 ~ 4CT
Abaid [12] 32 40–46Gy 3CT+RT+3CT 6CT
Lan [13] 35 44–64Gy 1/2/3/4/5CT+RT+CT 3 ~ 6CT
Dogan [5] 11 45–50.4Gy 3CT+RT+3CT 6CT
RT radiotherapy, CT chemotherapy; Radiation therapy dosage and irradiated
fields were determined by disease site, lymph node status and the discretion
of the treating radiation oncologist
Table 5 Summary of recurrence from recent “sandwich” regimens




Lupe [6] 43 49 5 44
Geller [7] 41 24 2 22
Einstein [8] 27 37 15 22
Fields [9] 30 38 7 31
Secord [10] 45 24 4 20
Geller [11] 23
Abaid [12] 32 16 9 7
Lan [13] 35 35 8 27
Dogan [5] 11 9 9 0
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on a q21-day schedule followed by irradiation (45–50.4 Gy)
or six cycles of the same chemotherapy followed by radio-
therapy. 11 patients had sandwich therapy and 14 patients
were treated by 6 cycles of chemotherapy followed by
radiotherapy. Three out of the five patients who could not
complete in the sandwich therapy group had pelvic and
para-aortic radiotherapy. In sandwich group, acute
radiotherapy related grade 1–2 gastrointestinal and
genitourinary system toxicities were observed in 72.8
and 63.6 % of patients, respectively. Undesired treatment
breaks in the course of radiotherapy were also observed in
six patients for this group and all of them had pelvic and
para-aortic radiotherapy. They concluded the sandwich
chemo-radiotherapy seems to be more toxic particularly
for patients who had pelvic and para-aortic irradiation.
The author suggests that it is a good choice to delay radio-
therapy after all cycles of chemotherapy for patients with
para-aortic radiotherapy [5].
Dagon, et al. also showed the median follow-up was
18 months (range 12–53 months). A patient hadTable 4 Summary of outcomes from recent “sandwich” regimens
Study N Completed (%) Recurrence (%) Neutropenia
Lupe [6] 43 81 49
Geller [7] 41 24 19
Einstein [8] 27 70 37 18
Fields [9] 30 97 38 42
Secord [10] 45 24 33
Geller [11] 23
Abaid [12] 32 94 16 3
Lan [13] 35 74 35
Dogan [5] 11 55 9 64
PFS Progression Free Survival, DFS Disease Free Survival, OS Overall Survivalsandwich therapy was detected of vaginal vault recur-
rence at 17 months after primary treatment [5].
In these “sandwich” regimens, every patient accepted
pelvic radiotherapy (Table 3). Fields were extended and
addition of HDR (high doses radiotherapy) vaginal vault
brachytherapy was left to the discretion of the treating
radiation oncologist.
Tables 4 and 5 show summary of study details with as-
sociated outcomes from recent “sandwich” regimens.
From Table 5, the low rate of local recurrence is not-
able after the sandwich therapy for high-risk endometrial
cancer patients.
Discussion
For high-risk endometrial cancer, we have not yet achieved
optimal outcomes with currently available therapies [14].
Using chemotherapy alone has been associated with
high pelvic relapse rates. The use of adjuvant chemo-
radiotherapy seems to be promising with acceptable
recurrence rates.
In theory, sequential of both radiation and chemother-
apy modalities should limit the overall toxicity and allow
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and radiation in women of high risk EC. The most stud-
ies showed the sandwich approach to treating high risk
EC patients is feasible, even patients with advanced age
and late stage.
In past studies, most patients were treated with pacli-
taxel and carboplatin chemotherapy. Many physicians
have already adopted the carboplatin and paclitaxel as
standard regimens. Other regimens included ifosfamide
and cisplatin.
In our review the low pelvic relapse rate associated with
“sandwich” treatment protocol was found. But comparing
survival rates is a problem in light of the substantial
differences between patient populations selected for
each study. The different conclusions of tolerability,
acute toxicity, recurrence, DFS and OS rates in sandwich
therapy in high risk of EC may be due to the different
histological subtype, dose of therapy and the combination
ways of radiotherapy.
A larger multi-institutional clinical trial should be con-
sidered to confirm these pilot data.
Conclusion
The “sandwich” therapy for high risk EC appears to be
tolerable and effective. Future randomized trials are ne-
cessary to compare chemo radiotherapy given in the
“sandwich” fashion to other means of sequencing these
treatment modalities. For example the randomized trial can
be designed to compare “sandwich chemo-radiotherapy”
with all cycles of chemotherapy followed by adjuvant radio-
therapy with respect to tolerability and acute toxicity. And
it is also necessary to define which population is best suited
for “sandwich” adjuvant therapy.
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